Andera Partners’ Portfolio Company Tubulis Secures €128 Million in Series B2 Financing

Andera Partners, an investment entity, has contributed to the substantial financing of Tubulis, amassing €128 million in its Series B2 financing round. This round saw participation from a notable consortium of global venture capitals, including EQT Life Sciences and Nextech Invest, alongside new entrants from the US such as Frazier Life Sciences and Deep Track Capital. The influx of capital is designated to expedite the clinical evaluations of Tubulis' innovative Antibody Drug Conjugates (ADCs), particularly focusing on the development of TUB-030 and TUB-040 aimed at combating solid tumors.

Tubulis aims to refine its ADC offerings by leveraging the allocated funds towards propelling its technologies into clinical proof-of-concept phases. Specifically, it will address the tumor-antigen Napi2b and the antigen 5T4, which are prevalent in ovarian, lung, and various solid tumors. Additionally, the proceeds will facilitate Tubulis' technological expansion and its strategic entrenchment in the US through the establishment of a subsidiary. This financial milestone underscores the biotech firm's ambition to transition into a clinical-stage entity and to fortify its stature within the global ADC market.

The firm’s proprietary technology and innovative approach to ADC development have positioned Tubulis to potentially lead in the ADC sector, with the ambition of enhancing therapeutic outcomes for patients with solid tumors.